Literature DB >> 15564497

Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.

Miguel Islas-Ohlmayer1, Angela Padgett-Thomas, Rana Domiati-Saad, Michael W Melkus, Petra D Cravens, Maria del P Martin, George Netto, J Victor Garcia.   

Abstract

Epstein-Barr virus (EBV)-induced lymphoproliferative disease is an important complication in the context of immune deficiency. Impaired T-cell immunity allows the outgrowth of transformed cells with the subsequent production of predominantly B-cell lymphomas. Currently there is no in vivo model that can adequately recapitulate EBV infection and its association with B-cell lymphomas. NOD/SCID mice engrafted with human CD34(+) cells and reconstituted mainly with human B lymphocytes may serve as a useful xenograft model to study EBV infection and pathogenesis. We therefore infected reconstituted mice with EBV. High levels of viral DNA were detected in the peripheral blood of all infected mice. All infected mice lost weight and showed decreased activity levels. Infected mice presented large visible tumors in multiple organs, most prominently in the spleen. These tumors stained positive for human CD79a, CD20, CD30, and EBV-encoded RNAs and were light chain restricted. Their characterization is consistent with that of large cell immunoblastic lymphoma. In addition, tumor cells expressed EBNA1, LMP1, and LMP2a mRNAs, which is consistent with a type II latency program. EBV(+) lymphoblastoid cell lines expressing human CD45, CD19, CD21, CD23, CD5, and CD30 were readily established from the bone marrow and spleens of infected animals. Finally, we also demonstrate that infection with an enhanced green fluorescent protein (EGFP)-tagged virus can be monitored by the detection of infected EGFP(+) cells and EGFP(+) tumors. These data demonstrate that NOD/SCID mice that are reconstituted with human CD34(+) cells are susceptible to infection by EBV and accurately recapitulate important aspects of EBV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564497      PMCID: PMC533956          DOI: 10.1128/JVI.78.24.13891-13900.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells.

Authors:  G Niedobitek; A Agathanggelou; H Herbst; L Whitehead; D H Wright; L S Young
Journal:  J Pathol       Date:  1997-06       Impact factor: 7.996

2.  Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.

Authors:  I A Darenkov; M A Marcarelli; G P Basadonna; A L Friedman; K M Lorber; J G Howe; J Crouch; M J Bia; A S Kliger; M I Lorber
Journal:  Transplantation       Date:  1997-09-27       Impact factor: 4.939

3.  Human tumor models in the severe combined immune deficient (scid) mouse.

Authors:  G D Paine-Murrieta; C W Taylor; R A Curtis; M H Lopez; R T Dorr; C S Johnson; C Y Funk; F Thompson; E M Hersh
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

4.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

Authors:  Zhensheng Liu; Barbara Savoldo; Helen Huls; Teresita Lopez; Adrian Gee; Jeffery Wilson; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  Recent Results Cancer Res       Date:  2002

5.  Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation.

Authors:  S Harada; E Kieff
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

6.  Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.

Authors:  Patrizia Comoli; Massimo Labirio; Sabrina Basso; Fausto Baldanti; Paolo Grossi; Milena Furione; Mario Viganò; Roberto Fiocchi; Giorgio Rossi; Fabrizio Ginevri; Bruno Gridelli; Antonia Moretta; Daniela Montagna; Franco Locatelli; Giuseppe Gerna; Rita Maccario
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

7.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

Authors:  C M Rooney; C A Smith; C Y Ng; S K Loftin; J W Sixbey; Y Gan; D K Srivastava; L C Bowman; R A Krance; M K Brenner; H E Heslop
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

8.  Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.

Authors:  Tanzina Haque; Gwen M Wilkie; Clare Taylor; Peter L Amlot; Parvez Murad; Angela Iley; Dilani Dombagoda; Kate M Britton; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Lancet       Date:  2002-08-10       Impact factor: 79.321

Review 9.  SCID mouse models of human stem cell engraftment.

Authors:  D L Greiner; R A Hesselton; L D Shultz
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

Review 10.  A mouse model for infectious mononucleosis.

Authors:  Emilio Flaño; David L Woodland; Marcia A Blackman
Journal:  Immunol Res       Date:  2002       Impact factor: 4.505

View more
  31 in total

1.  Co-transplantation of fetal bone tissue facilitates the development and reconstitution in human B cells in humanized NOD/SCID/IL-2Rγnull (NSG) mice.

Authors:  Miyoung Kim; Bongkum Choi; So Yong Kim; Ji-Hyuk Yang; Cheong Rae Roh; Ki-Young Lee; Sung Joo Kim
Journal:  J Clin Immunol       Date:  2011-05-05       Impact factor: 8.317

Review 2.  New generation humanized mice for virus research: comparative aspects and future prospects.

Authors:  Ramesh Akkina
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

Review 3.  The use of BLT humanized mice to investigate the immune reconstitution of the gastrointestinal tract.

Authors:  Angela Wahl; J Victor Garcia
Journal:  J Immunol Methods       Date:  2014-06-18       Impact factor: 2.303

4.  Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice.

Authors:  Eun Kyung Lee; Eun Hye Joo; Kyung-A Song; Bongkum Choi; Miyoung Kim; Seok-Hyung Kim; Sung Joo Kim; Myung-Soo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

5.  T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice.

Authors:  Frank Heuts; Martin E Rottenberg; Daniel Salamon; Eahsan Rasul; Monika Adori; George Klein; Eva Klein; Noemi Nagy
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

6.  A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.

Authors:  Shi-Dong Ma; Subramanya Hegde; Ken H Young; Ruth Sullivan; Deepika Rajesh; Ying Zhou; Ewa Jankowska-Gan; William J Burlingham; Xiaoping Sun; Margaret L Gulley; Weihua Tang; Jenny E Gumperz; Shannon C Kenney
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

7.  Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model.

Authors:  M Shane Smith; Devorah C Goldman; Alexis S Bailey; Dana L Pfaffle; Craig N Kreklywich; Doran B Spencer; Florence A Othieno; Daniel N Streblow; J Victor Garcia; William H Fleming; Jay A Nelson
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

8.  Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice.

Authors:  Qingfeng Chen; Maroun Khoury; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

9.  Macrophages sustain HIV replication in vivo independently of T cells.

Authors:  Jenna B Honeycutt; Angela Wahl; Caroline Baker; Rae Ann Spagnuolo; John Foster; Oksana Zakharova; Stephen Wietgrefe; Carolina Caro-Vegas; Victoria Madden; Garrett Sharpe; Ashley T Haase; Joseph J Eron; J Victor Garcia
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

10.  Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.

Authors:  Till Strowig; Cagan Gurer; Alexander Ploss; Yi-Fang Liu; Frida Arrey; Junji Sashihara; Gloria Koo; Charles M Rice; James W Young; Amy Chadburn; Jeffrey I Cohen; Christian Münz
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.